Autor: |
Jason G, Kettle, Sharan K, Bagal, Sue, Bickerton, Michael S, Bodnarchuk, Scott, Boyd, Jason, Breed, Rodrigo J, Carbajo, Doyle J, Cassar, Atanu, Chakraborty, Sabina, Cosulich, Iain, Cumming, Michael, Davies, Nichola L, Davies, Andrew, Eatherton, Laura, Evans, Lyman, Feron, Shaun, Fillery, Emma S, Gleave, Frederick W, Goldberg, Lyndsey, Hanson, Stephanie, Harlfinger, Martin, Howard, Rachel, Howells, Anne, Jackson, Paul, Kemmitt, Gillian, Lamont, Scott, Lamont, Hilary J, Lewis, Libin, Liu, Michael J, Niedbala, Christopher, Phillips, Radek, Polanski, Piotr, Raubo, Graeme, Robb, David M, Robinson, Sarah, Ross, Matthew G, Sanders, Michael, Tonge, Rebecca, Whiteley, Stephen, Wilkinson, Junsheng, Yang, Wenman, Zhang |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
Journal of medicinal chemistry. 65(9) |
ISSN: |
1520-4804 |
Popis: |
KRAS is an archetypal high-value intractable oncology drug target. The glycine to cysteine mutation at codon 12 represents an Achilles heel that has now rendered this important GTPase druggable. Herein, we report our structure-based drug design approach that led to the identification of |
Databáze: |
OpenAIRE |
Externí odkaz: |
|